Tirzepatide meets primary endpoint in both the phase III SURPASS-3 and SURPASS-5 clinical trials in type 2 diabetes

Tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist led to superior HbA1c and body weight reductions compared to titrated insulin degludec in SURPASS-3 at 52 weeks and compared to placebo in SURPASS-5 at 40 weeks.

Source:

Biospace Inc.